Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

18.11
-1.1600-6.02%
Post-market: 18.300.1900+1.05%17:58 EDT
Volume:3.79M
Turnover:68.95M
Market Cap:835.32M
PE:82.32
High:19.16
Open:19.06
Low:17.83
Close:19.27
52wk High:63.65
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:1.94
T/O Rate:13.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2200
EPS(LYR):1.80
ROE:5.10%
ROA:-0.48%
PB:3.43
PE(LYR):10.06

Loading ...

Oddity Tech Shares Fall After Customer-Acquisition Costs Soar

Dow Jones
·
Jun 02

Oddity sees Q2 revenue down 25%-30%

TIPRANKS
·
Jun 02

ODDITY Tech Swings to Q1 Loss as Ad Disruption Hits Sales but Steps Up Buybacks

TIPRANKS
·
Jun 02

Oddity Tech Swings to Q1 Adjusted Loss, Net Revenue Declines

MT Newswires Live
·
Jun 02

ODDITY Tech Q1 revenue declines

Reuters
·
Jun 02

ODDITY Tech Q1 Adj. EPS $(0.17) Misses $0.01 Estimate, Sales $197.940M Beat $187.940M Estimate

Benzinga Earnings
·
Jun 02

Earnings Flash (ODD) ODDITY Tech Posts Q1 Adjusted Loss $0.17 a Share

MT Newswires Live
·
Jun 02

Oddity Q1 FY26 turns to net loss of $21.4 million; revenue drops 26% to $197.9 million

Reuters
·
Jun 02

BRIEF-ODDITY Tech Q1 Adjusted EPS USD -0.17

Reuters
·
Jun 02

Press Release: ODDITY Tech Reports First Quarter 2026 Results, Makes Progress Toward Normalization

Dow Jones
·
Jun 02

Oddity Tech Outlook Q2 Net Revenue to Decline Between 25 and 30%

THOMSON REUTERS
·
Jun 02

Oddity Tech Q1 Revenue USD 197.9 Million

THOMSON REUTERS
·
Jun 02

Oddity Tech Outlook Q2 Adjusted Ebitda USD 8-10 Million

THOMSON REUTERS
·
Jun 02

Oddity Tech Q1 Gross Margin 69.7%

THOMSON REUTERS
·
Jun 02

Oddity Tech Q1 EPS USD -0.38

THOMSON REUTERS
·
Jun 02

Oddity Tech Q1 Adjusted Ebitda USD -7 Million

THOMSON REUTERS
·
Jun 02

Oddity Tech - Expects Positive Adj Ebitda for Full Year 2026

THOMSON REUTERS
·
Jun 02

Oddity Tech Reports First Quarter 2026 Results, Makes Progress Toward Normalization

THOMSON REUTERS
·
Jun 02

U.S. Earnings Preview: Before Market Open June 2

Dow Jones
·
Jun 02

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

GlobeNewswire
·
Jun 01